Trial Profile

Phase 1 Study of Tasquinimod Alone and in Combination with Standard Therapy for Relapsed or Refractory Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tasquinimod (Primary) ; Dexamethasone; Ixazomib; Lenalidomide
Indications Multiple myeloma
Focus Adverse reactions

Most Recent Events

09 Jun 2025 According to an Active Biotech media release,The results from this study were presented in a poster at the American Society of Clinical Oncology (ASCO) annual meeting May 30 -June 1 2025.
09 Jun 2025 Results presented in the Active Biotech Media Release
23 May 2025 According to an Active Biotech media release,The results from this study will be presented in a poster at the American Society of Clinical Oncology (ASCO) annual meeting May 30-June 1 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com